Summary
GlobalData's Medical Devices sector report, “Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Medical Devices Pipeline Assessment, 2016" provides an overview of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Companies Mentioned
AnGes MG, Inc.
AngioCure, Inc.
AVIDAL Vascular GmbH
Bayer HealthCare AG
Contego Medical, LLC
Elixir Medical Corporation
eucatech AG
Lifetech Scientific (Shenzhen) Co., Ltd.
Medtronic plc
Micell Technologies, Inc.
Nipro Corporation
NuVascular Technologies Inc
QT Vascular Ltd.
QualiMed Innovative Medizinprodukte GmbH
Rontis AG
SiL Vascular Ltd
SurModics, Inc.
Terumo Corporation
The Spectranetics Corporation
Vascular Nanotransfer Technologies
'
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Overview 8
3 Products under Development 9
3.1 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 9
3.2 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 10
3.3 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 11
3.4 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 12
3.5 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 13
4 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products under Development by Companies 14
4.1 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development 14
4.2 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 15
5 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies and Product Overview 16
5.1 AnGes MG, Inc. Company Overview 16
5.1.1 AnGes MG, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
5.2 AngioCure, Inc. Company Overview 18
5.2.1 AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18
5.3 AVIDAL Vascular GmbH Company Overview 19
5.3.1 AVIDAL Vascular GmbH Pipeline Products & Ongoing Clinical Trials Overview 19
5.4 Bayer HealthCare AG Company Overview 20
5.4.1 Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview 20
5.5 Contego Medical, LLC Company Overview 22
5.5.1 Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 22
5.6 Elixir Medical Corporation Company Overview 23
5.6.1 Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
5.7 eucatech AG Company Overview 24
5.7.1 eucatech AG Pipeline Products & Ongoing Clinical Trials Overview 24
5.8 Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview 25
5.8.1 Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 25
5.9 Medtronic plc Company Overview 26
5.9.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 26
5.10 Micell Technologies, Inc. Company Overview 28
5.10.1 Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
5.11 Nipro Corporation Company Overview 30
5.11.1 Nipro Corporation Pipeline Products & Ongoing Clinical Trials Overview 30
5.12 NuVascular Technologies Inc Company Overview 31
5.12.1 NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 31
5.13 QT Vascular Ltd. Company Overview 32
5.13.1 QT Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview 32
5.14 QualiMed Innovative Medizinprodukte GmbH Company Overview 36
5.14.1 QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview 36
5.15 Rontis AG Company Overview 37
5.15.1 Rontis AG Pipeline Products & Ongoing Clinical Trials Overview 37
5.16 SiL Vascular Ltd Company Overview 38
5.16.1 SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
5.17 SurModics, Inc. Company Overview 39
5.17.1 SurModics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
5.18 Terumo Corporation Company Overview 44
5.18.1 Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview 44
5.19 The Spectranetics Corporation Company Overview 46
5.19.1 The Spectranetics Corporation Pipeline Products & Ongoing Clinical Trials Overview 46
5.20 Vascular Nanotransfer Technologies Company Overview 52
5.20.1 Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview 52
6 Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Recent Developments 54
6.1 Jul 21, 2016: Federal Circuit Court Rules in Appeal 54
6.2 Jul 20, 2016: 12-month Results of the ILLUMENATE European Randomized Clinical Trial to be Presented at the Amputation Prevention Symposium 54
6.3 Jul 15, 2016: Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 54
6.4 Jul 15, 2016: Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 55
6.5 Jul 13, 2016: Medtronic Receives FDA Approval for IN.PACT Admiral DCB 150 mm Lengths 55
6.6 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors 56
6.7 Jun 30, 2016: FTSE Russell Selects Daiichi Sankyo for FTSE4Good Global Index 56
6.8 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic 56
6.9 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation 57
6.10 Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day 57
6.11 Jun 01, 2016: Second Interim Analysis on ILLUMENATE Global Study Presented on Spectranetics’ Stellarex drug-coated balloon at NCVH 58
6.12 May 31, 2016: Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results 59
6.13 May 16, 2016: iVascular Receives CE Mark Approval for LUMINOR 18 Drug Eluting Balloon 61
6.14 May 12, 2016: Daiichi Sankyo Announces Changes to Representative Director and Members of the Board 62
6.15 May 06, 2016: The outcome of arbitration proceeding with certain former shareholders of Ranbaxy 62
6.16 Apr 26, 2016: 12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics’ Stellarex drug-coated balloon at Charing Cross 63
6.17 Apr 26, 2016: Medtronic IN.PACT Admiral DCB Maintains Durable, Consistent and Safe Outcomes in Challenging Peripheral Cases 64
6.18 Apr 25, 2016: QT Vascular Submits IDE Requesting Permission to Begin Pivotal Trial of Its Drug-Coated Chocolate Balloon in The United States 66
6.19 Apr 06, 2016: SurModics Announces First Patient Enrolled in IDE Study of SurVeil Drug-Coated Balloon 67
6.20 Feb 10, 2016: QT Vascular Announces Another Positive Outcome in Litigation with Spectranetics/Angioscore 68
6.21 Jan 26, 2016: BIOTRONIK Announces Expansion Of Passeo-18 Lux Drug-Coated Balloon Portfolio 68
6.22 Jan 11, 2016: Medtronic IN.PACT Admiral DEB Receives CE Mark For Treatment Of AV Access In Patients With End-Stage Renal Disease 69
6.23 Dec 14, 2015: Medtronic Announces New High-Tech Facility in Galway; Building on Global Synergies 70
6.24 Nov 26, 2015: Update On AngioScore Litigation - QT Vascular Ltd 71
6.25 Nov 20, 2015: BIOTRONIK Announces Improved Patient Outcomes with Innovative “Combination Therapy” for Peripheral Artery Disease 71
6.26 Nov 02, 2015: IN.PACT Admiral Drug-Coated Balloon Cost-Effectiveness Study and Global Study Results of In-Stent Restenosis Population Highlighted in Late Breaking Clinical Trials at VIVA 2015 72
6.27 Nov 02, 2015: Medtronic Begins REALITY Study To Assess IN.PACT Admiral DCB In Patients With PAD 74
6.28 Oct 14, 2015: Medtronic Drug-Coated Balloon Sustains Superiority Over Balloon Angioplasty at Two Years in Patients with Peripheral Arterial Disease 75
6.29 Oct 05, 2015: SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon 76
6.30 Oct 05, 2015: QT Vascular Announces Interim Clinical Trial Results Of Chocolate Touch 78
6.31 Oct 05, 2015: SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon 79
6.32 Sep 15, 2015: New Technique at Morris Hospital Improves Treatment of Peripheral Artery Disease 80
6.33 Sep 07, 2015: QT Vascular Announces CE Mark Clearance Of Chocolate Touch By LRQA 0088 80
6.34 Aug 03, 2015: CMS Grants New Technology Add-On Payment for Inpatient Use of Medtronic's Drug-Coated Balloon 81
6.35 Jul 29, 2015: Spectranetics Completes Enrollment in ILLUMENATE Pivotal Study to Assess Safety and Efficacy of Stellarex Drug-Coated Balloon Technology 82
7 Appendix 84
7.1 Methodology 84
7.2 About GlobalData 86
7.3 Contact Us 86
7.4 Disclaimer 87
1.1 List of Tables
Table 1: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 9
Table 2: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 10
Table 3: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 11
Table 4: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 12
Table 5: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 13
Table 6: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development 14
Table 7: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 15
Table 8: AnGes MG, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
Table 9: Collategene Drug-Eluting Balloon Catheter - Product Status 16
Table 10: Collategene Drug-Eluting Balloon Catheter - Product Description 17
Table 11: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Status 17
Table 12: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Description 17
Table 13: AngioCure, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18
Table 14: AngioCure TOP-C Smart Balloon Catheter - Product Status 18
Table 15: AngioCure TOP-C Smart Balloon Catheter - Product Description 18
Table 16: AVIDAL Vascular GmbH Pipeline Products & Ongoing Clinical Trials Overview 19
Table 17: WOMBAT - Peripheral Version - Product Status 19
Table 18: WOMBAT - Peripheral Version - Product Description 19
Table 19: Bayer HealthCare AG Pipeline Products & Ongoing Clinical Trials Overview 20
Table 20: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Status 20
Table 21: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Description 21
Table 22: Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 22
Table 23: Tibial Artery Drug Eluting Balloon - Product Status 22
Table 24: Tibial Artery Drug Eluting Balloon - Product Description 22
Table 25: Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
Table 26: Peripheral Vascular Resorbable Scaffold - Product Status 23
Table 27: Peripheral Vascular Resorbable Scaffold - Product Description 23
Table 28: eucatech AG Pipeline Products & Ongoing Clinical Trials Overview 24
Table 29: Support - Product Status 24
Table 30: Support - Product Description 24
Table 31: Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 25
Table 32: PTA Drug Eluting Balloon - Product Status 25
Table 33: PTA Drug Eluting Balloon - Product Description 25
Table 34: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 26
Table 35: DCB BTK - Product Status 26
Table 36: DCB BTK - Product Description 27
Table 37: Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
Table 38: Drug-Coated Balloon - Product Status 28
Table 39: Drug-Coated Balloon - Product Description 29
Table 40: Nipro Corporation Pipeline Products & Ongoing Clinical Trials Overview 30
Table 41: Peripheral Drug-Eluting Balloon - Product Status 30
Table 42: Peripheral Drug-Eluting Balloon - Product Description 30
Table 43: NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 31
Table 44: NuSpun DE Balloon - Product Status 31
Table 45: NuSpun DE Balloon - Product Description 31
Table 46: QT Vascular Ltd. Pipeline Products & Ongoing Clinical Trials Overview 32
Table 47: Chocolate Touch PTA Drug Coated Balloon - Product Status 32
Table 48: Chocolate Touch PTA Drug Coated Balloon - Product Description 33
Table 49: Silk PTA Balloon Catheter - Product Status 33
Table 50: Silk PTA Balloon Catheter - Product Description 33
Table 51: QT Vascular Ltd. - Ongoing Clinical Trials Overview 34
Table 52: Chocolate Touch PTA Drug Coated Balloon - First in Human Evaluation of the Drug-coated Chocolate Balloon for Percutaneous Transluminal Revascularization of Infrainguinal Arterial Disease 35
Table 53: Chocolate Touch PTA Drug Coated Balloon - Pivotal Trial of Drug-coated Chocolate Balloon in The United States 35
Table 54: QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview 36
Table 55: Kinesyx-Based Peripheral Drug Coated Balloon - Product Status 36
Table 56: Kinesyx-Based Peripheral Drug Coated Balloon - Product Description 36
Table 57: Rontis AG Pipeline Products & Ongoing Clinical Trials Overview 37
Table 58: Drug Eluting Dilatation Catheter - Product Status 37
Table 59: Drug Eluting Dilatation Catheter - Product Description 37
Table 60: SiL Vascular Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
Table 61: Peripheral Vascular Balloon - Product Status 38
Table 62: Peripheral Vascular Balloon - Product Description 38
Table 63: SurModics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
Table 64: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Status 39
Table 65: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Description 40
Table 66: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Status 40
Table 67: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Description 40
Table 68: SurVeil Drug Coated Balloon - SFA - Product Status 41
Table 69: SurVeil Drug Coated Balloon - SFA - Product Description 41
Table 70: SurModics, Inc. - Ongoing Clinical Trials Overview 42
Table 71: SurVeil Drug Coated Balloon - SFA - A Prospective, Multi-center, Single-arm Trial to Assess the Safety and Feasibility of the SurModics Drug Coated Balloon in the Treatment of Subjects with De Novo Lesions of the Femoropopliteal Artery 43
Table 72: Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview 44
Table 73: Drug Coated Balloon Catheter - Product Status 44
Table 74: Drug Coated Balloon Catheter - Product Description 45
Table 75: The Spectranetics Corporation Pipeline Products & Ongoing Clinical Trials Overview 46
Table 76: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Status 46
Table 77: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Description 47
Table 78: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Status 47
Table 79: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Description 48
Table 80: The Spectranetics Corporation - Ongoing Clinical Trials Overview 49
Table 81: Stellarex Drug Coated Balloon - Superficial Femoral Artery - ILLUMENATE First-in-Human (FIH) Study on the Safety and Effectiveness of Covidien’s Advanced Drug-coated Balloon (DCB) Technology 50
Table 82: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Prospective, Single-arm, Global Multi-center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery and/or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon (ILLUMENATE GLOBAL) 50
Table 83: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Prospective, Single-arm, Multi-center, Pharmacokinetic Study to Evaluate Treatment of Obstructive Superficial Femoral Artery or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon 51
Table 84: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Stellarex Vascular E-Registry 51
Table 85: Vascular Nanotransfer Technologies Pipeline Products & Ongoing Clinical Trials Overview 52
Table 86: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Status 52
Table 87: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Description 52
Table 88: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Status 53
Table 89: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Description 53
Table 90: Glossary 85
1.2 List of Figures
Figure 1: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 9
Figure 2: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 10
Figure 3: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 11
Figure 4: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 12
Figure 5: Peripheral Transluminal Angioplasty Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 13
